Wednesday, January 08, 2020 10:20:18 PM
dmiller,
I see your point on finishing green. No I haven't counted the days but the fact remains our SP is low for all of the positive news and obstacles that have been released or published over the past 14/16 months.
Im not all in on this stock and trade core positions on others, not AMRN. I have a fairly low cost basis (in the $12 range). No complaints but the SP has not held a gain so far and I haven't sold. Im in no hurry to let go of it. But you have to admit It is a frustrating stock. I have had a ton more gains with others. Im not a professional trader but Array, AXSM, ACAD and REGI were not too hard to figure out.
These folks that are all in or have a large position in AMRN (mine isn't exactly small) are venting and asking questions. They are not here to get bashed on by someone with more experience. So in that regard, how about being just a little more understanding on what a message board is for and please just stop with the exuberant BS that you are throwing out at these folks. Its actually less productive than letting folks vent a bit. If you would really like to vest your opinion on this board, how about being productive and helping some folks out on their trading decisions. TIA.
I see your point on finishing green. No I haven't counted the days but the fact remains our SP is low for all of the positive news and obstacles that have been released or published over the past 14/16 months.
Im not all in on this stock and trade core positions on others, not AMRN. I have a fairly low cost basis (in the $12 range). No complaints but the SP has not held a gain so far and I haven't sold. Im in no hurry to let go of it. But you have to admit It is a frustrating stock. I have had a ton more gains with others. Im not a professional trader but Array, AXSM, ACAD and REGI were not too hard to figure out.
These folks that are all in or have a large position in AMRN (mine isn't exactly small) are venting and asking questions. They are not here to get bashed on by someone with more experience. So in that regard, how about being just a little more understanding on what a message board is for and please just stop with the exuberant BS that you are throwing out at these folks. Its actually less productive than letting folks vent a bit. If you would really like to vest your opinion on this board, how about being productive and helping some folks out on their trading decisions. TIA.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
